How oppositionality, inattention, and hyperactivity affect response to atomoxetine versus methylphenidate: a pooled
Gregory W van Wyk1, Philip L Hazell, Michael R Kohn
1Eli Lilly Australia Pty Ltd, West Ryde, NSW, Australia. van_wyk_gregory_wayne@lilly.com
Journal of Attention Disorders
|February 4, 2011
Summary
This study found that oppositional defiant disorder (ODD), inattention, and hyperactivity-impulsivity do not change how well atomoxetine or methylphenidate work for core ADHD symptoms. Treatment response was equivalent between the two medications.
Area of Science:
- Child and Adolescent Psychiatry
- Pharmacology
- Neuroscience
Background:
- Attention-Deficit/Hyperactivity Disorder (ADHD) is a common neurodevelopmental disorder.
- Comorbid conditions like oppositional defiant disorder (ODD) and specific symptom presentations (inattention, hyperactivity-impulsivity) may influence treatment efficacy.
- Atomoxetine and methylphenidate are common pharmacological treatments for ADHD.
Purpose of the Study:
- To evaluate the impact of oppositional defiant disorder (ODD) and ADHD symptom subtypes on treatment response.
- To compare the efficacy of atomoxetine versus methylphenidate in children and adolescents with ADHD.
- To determine if specific symptom thresholds influence medication effectiveness.
Main Methods:
- Systematic review and meta-analysis of 7 randomized controlled trials (RCTs) with at least 6 weeks of follow-up.
- Included data from 1,391 children and adolescents (823 on atomoxetine, 568 on methylphenidate).
- Primary outcome measure was a ≥40% reduction in ADHD Rating Scale-IV core symptoms.
Main Results:
- No significant difference in response rates between atomoxetine and methylphenidate was observed, regardless of ODD status (mean difference 0.6%).
- Response rate differences for inattention and hyperactivity-impulsivity symptom groups were -3.1% and -4.9%, respectively, with overlapping confidence intervals.
- Significant heterogeneity was noted in the subgroup of patients without ODD.
Conclusions:
- Meeting threshold criteria for ODD, inattention, or hyperactivity-impulsivity did not significantly alter the core ADHD symptom response to atomoxetine compared to methylphenidate.
- Atomoxetine and methylphenidate demonstrated equivalent efficacy for core ADHD symptoms in this patient population.
- Further research may explore nuanced differences in specific symptom domains or treatment durability.
More Related Videos
Related Concept Videos
01:30Attention-Deficit/Hyperactivity Disorder
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
01:28Adrenergic Agonists: Mixed-Action Agents
Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
01:25Adrenergic Agonists: Indirect-Acting Agents
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...